KCT0006010招募中未知
A single center, randomized, evaluator and subject blind, placebo controlled, parallel, phase 1/2 study for the anti-wrinkle efficacy assessment and safety evaluation by treating cluster of autologous dermal fibroblasts, 3D-F in patients with bilateral Crow’s feet
S.Biomedics0 个研究点目标入组 80 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Participants of ages 19 and older
- •2) Those with at least 3 points (Moderate) of the IGA-LCL severity scale on both sides in the rest state during screening
- •3) Those who have visually symmetrical periorbital wrinkles on both sides and have the same IGA-LCL severity scale score in the rest state
- •4) Those who agreed to discontinue all dermatological treatments including facial wrinkle improvement during this study period
- •5) Subjects with healthy and undamaged skin at the sampling area (e.g., behind the ears, inside of the arms, armpits, groin, etc.)
- •6) Those who meet the following criteria based on the blood test at screening or baseline visits
- •- White Blood Cell : =4.5x10^3/µl and =11.0x10^3/µl
- •- Platelet count : =100x10^3/µl
- •- Hemoglobin : =9 g/dL
- •7) Those who sign the written consent form after hearing the explanation of the purpose, method, and efficacy of this study
- •8) Those who can be followed up during the study period
排除标准
- •1) Those with arterial bleeding or severe variceal bleeding in the body
- •2) Those with hypersensitivity to bovine protein or gentamicin
- •3) Pregnant and breast-feeding or who planning to conceive within six months of clinical trial medication
- •4) Out of who are pregnant or breast-feeding and A woman who is likely to be pregnant in a postmenopausal or a state of non-Infertility surgery and men with reproductive abilities not willing or planning to use the appropriate contraception defined in this clinical trial during their participation in clinical trials
- •5) Those with or suspected of having autoimmune diseases (e.g., myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, etc.)
- •6) At the screening visit, patients with chronic skin disease or such a medical history
- •7) Those with a medical history or a positive test result for any of the following: hepatitis C virus antibody (HCV Ab), hepatitis B surface antigen (HBsAg), human immunodeficiency virus-1 (HIV-1) antibody, human immunodeficiency virus-2 (HIV-2) antibody
- •(However, if HCV is proven to be completely cured based on the HCV RNA test, he/she can be enrolled as a subject.)
- •8) Those with severe heart diseases (e.g., myocardial infarction, heart failure, etc.) or severe liver diseases (e.g., hepatocirrhosis, liver failure, etc.) or severe kidney diseases (e.g., renal failure, etc.)
- •9) Those who have tumors or have such medical history within 5 years of screening
- •(However, if the malignant tumor does not relapse for more than 5 years, the candidate may be enrolled as a subject, and in the case of basal cell carcinoma or intradermal squamous cell carcinoma that does not relapse after resection, he/she can be enrolled as a subject.)
- •10) Those with genetic diseases affecting fibroblast or collagen
- •11) Those who have undergone anticoagulant therapy or antiplatelet therapy within 10 days prior to administration of the study drug, or those who are expected to need to receive them within 3 days after administration of the study drug
- •(However, if the drug is being administered at the time of screening, it is possible to participate in the clinical trial after a seven-day not administering medication period only if the temporary suspension does not pose a medical risk under the tester's judgment, tried tissue biopsy Schedule.)
- •12) Those who have active or infectious skin diseases (skin infection, inflammation, herpes, etc.), keloids, unhealed wounds or scars, tumors, etc. at the site where the study drug will be administered, or those who have previously received radiation treatment
- •13) Those with hypersensitivity to local anesthetics (however, those who agree to receive the procedure without applying an anesthetic agent due to hypersensitivity to local anesthetics, do not fall under this criteria.)
- •14) A person who has a history of significant adverse or hypersensitive reactions to the composition of medications for clinical trials
- •15) Those who have undergone procedures that can affect periorbital wrinkles, such as dermabrasion, skin regeneration, and plastic surgery, etc, among facial procedures including the eye area* or those who are expected to have such procedures during the study period
- •16) Those who participated in another study and received an investigational drug or used an investigational medical device within 6 months prior to participation in this study, or those who are scheduled to participate in another study during
研究者
相似试验
招募中
2 期
A Randomized, Single-center, Subject and Evaluator-blind, Matched-pair, Active-control, Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Revolax Deep with Lidocaine Administrations Compared to Restylane Defyne for Nasolabial Fold Corrections.HealthyNasolabial Fold correctionsNasolabial Fold correctionsDermal fillerHyaluronic acidRevolax Deep with LidocaineTCTR20240626005ACROSS Co., Ltd. (in HUGEL Inc.)100
已完成
不适用
medical device pivotal clinical study to assess the anti-adhesive effect and safety of ABT13107 compared to Hyalobarrier applied to postoperative intrauterineDiseases of the skin and subcutaneous tissueKCT0002393Medytox192
已完成
不适用
A single-center, randomized, investigator/subject-blind, adaptive single-ascending dose (Part 1) and multiple-ascending dose (Part 2), placebo-controlled, parallel study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6889450 following oral administration in healthy subjects.mental disorder characterized by abnormal social behavior and failure to recognize what is real10039628NL-OMON44416F. Hoffmann-La Roche Ltd.164
已完成
不适用
A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.psychiatric disordersSchizofrenia10039628NL-OMON36943Hoffmann-La Roche92
已完成
不适用
A clinical study of the safety and effectiveness of ionized atelocollagen based adhesion barrier(Collabarrier®) for adhesion prevention in spine surgeryDiseases of the musculoskeletal system and connective tissueKCT0007858Dalim Tissen68